Alfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $3.06 on Tuesday. Voyager Therapeutics, Inc. has a 52-week low of $2.81 and a 52-week high of $9.55. The business has a fifty day moving average of $4.25 and a two-hundred day moving average of $5.51. The stock has a market cap of $168.93 million, a PE ratio of 4.31 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the business earned $1.25 earnings per share. Analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics during the 4th quarter valued at $29,000. Tower Research Capital LLC TRC grew its holdings in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management increased its position in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares in the last quarter. Oxford Asset Management LLP bought a new position in shares of Voyager Therapeutics in the fourth quarter worth about $60,000. Finally, Intech Investment Management LLC acquired a new position in shares of Voyager Therapeutics during the third quarter worth approximately $74,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VYGR has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group lowered their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, March 13th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $13.97.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.